Cure rates for adults with acute myelogenous leukemia (AML) remain inadequate. Poor-risk features such as age ≥ 60, secondary AML including prior myelodysplasia (MDS) and treatment-related AML (t-AML), adverse cytogenetics, and hyperleukocytosis with extramedullary disease in the absence of "favorable" cytogenetics identify patients who are not only less likely to achieve remissions with cytotoxic chemotherapy but who are predisposed to shorter disease free survival despite intensive induction and post-remission therapies ([@b45-btt-2-491]; [@b32-btt-2-491]; [@b30-btt-2-491]; [@b2-btt-2-491]; [@b22-btt-2-491]).

In particular, the response rates and survival for adults age 70 and older with AML remain limited. Part of this poor response relates to the inability of very elderly patients (age ≥ 75) to tolerate intensive chemotherapy ([@b45-btt-2-491]; [@b2-btt-2-491]; [@b22-btt-2-491]). Equally important, however, is the genetic complexity and inherent resistance of these AMLs to the cytotoxic effects of traditional cytotoxic agents ([@b32-btt-2-491]; [@b30-btt-2-491]; [@b2-btt-2-491]). AMLs that arise in the older age group often do so from an antecedent hematologic disorder, mainly MDS which itself has evolved from a background of toxin exposures ([@b32-btt-2-491]; [@b2-btt-2-491]; [@b22-btt-2-491]). These MDS/AMLs exhibit a complex genetic profile, likely a result of cumulative genomic damage ([@b32-btt-2-491]).

Farnesyltransferase inhibitors (FTIs) are small molecule signal transduction inhibitors that inhibit critical cell growth and survival pathways (reviewed by [@b40-btt-2-491]). These agents are potent and selective competitive inhibitors of farnesyltransferase (FTase), an intracellular enzyme that catalyzes the transfer of the 15-carbon farnesyl moiety to a cysteine close to the C-terminus of a substrate polypeptide ([@b20-btt-2-491]; [@b5-btt-2-491]). A host of intracellular poly-peptides including the small GTP-binding polypeptides of the Ras, Rho-B and Rheb families, membrane lamins, and centromeric proteins (CENPs) that interact with microtubules to promote the completion of mitosis, are substrates for pre-nylation via FTase (reviewed by [@b63-btt-2-491]; [@b64-btt-2-491]; [@b40-btt-2-491]). Inhibiting farnesylation of these polypeptides leads to diminished cell proliferation and, in some model systems, cell death. These cytotoxic effects have been attributed to FTI-induced inhibition of prosurvival signaling by Akt ([@b37-btt-2-491]), the Rheb target mTOR ([@b16-btt-2-491]; [@b65-btt-2-491]; [@b72-btt-2-491]), or mitogen activated protein (MAP) kinases (reviewed by [@b63-btt-2-491]; [@b55-btt-2-491]). Alternatively, it has been suggested that FTIs induce apoptosis by causing upregulation of the proapoptotic Bcl-2 family members Bax ([@b6-btt-2-491]), Bak ([@b24-btt-2-491]), or PUMA ([@b31-btt-2-491]).

While FTIs were initially developed on the premise that FT inhibition would prevent the post- translational processing of Ras proteins and thereby impede an early junctional process in overall signal transduction (reviewed by [@b20-btt-2-491]; [@b5-btt-2-491]), it is not surprising that their activity is not necessarily limited to *ras* mutated tumors nor is the effect equal among tumors bearing different mutated *ras* isoforms. Indeed, FTIs are by no means "selective" as they target proteins involved in disparate pathways and thereby exert their cytotoxic effects by interdicting multiple mechanisms of cellular survival, including angiogenesis, cellular adhesion, and inhibition of apoptosis. This notion is further substantiated by DNA microarray analyses of selected AML cell lines and primary AML marrow blasts, where tipifarnib modulates the expression of several gene networks, upregulating multiple genes involved in apoptosis, immunity, cell-cell adhesion and cytoskeletal organization, while downregulating genes involved in proliferation and cell cycle progression ([@b59-btt-2-491]).

Hematologic malignancies provide a fertile testing ground for such agents because of the relative ease with which tumor tissue can be obtained throughout the therapeutic course. The ability to obtain target tissue in a longitudinal fashion provides a unique opportunity to define the relevant molecular components that may be modulated by these compounds and to relate those molecular effects to the clinical outcome. At present, three non-peptidomimetic FTIs are being tested clinically in a broad spectrum of hematologic malignancies: tipifarnib (R115777, Zarnestra), lonafarnib (SCH66336), and BMS-214662. To date, all three exhibit clinical and molecular biologic activities in diverse myeloid malignancies and MM with modest and acceptable toxicities. In particular, tipifarnib has exhibited clinical activity in patients with myeloid malignancies including elderly adults with AML who are not candidates for traditional cytotoxic chemotherapy ([@b38-btt-2-491]; [@b46-btt-2-491]), patients with high-risk MDS ([@b43-btt-2-491], [@b44-btt-2-491]; [@b25-btt-2-491]), myeloproliferative disorders ([@b54-btt-2-491]), and imatinib-resistant chronic myelogenous leukemia ([@b17-btt-2-491]). In this review, we will focus on the clinical development of tipifarnib for treatment of newly diagnosed AML, both as induction therapy for elderly adults with poor-risk AML and as maintenance therapy after achievement of first complete remission (CR) after induction and consolidation therapies for poor-risk AML.

Clinical trials of tipifarnib as induction therapy
==================================================

Single-agent studies ([Table 1](#t1-btt-2-491){ref-type="table"})
-----------------------------------------------------------------

The first clinical testing of FTIs in AML was a Phase I trial of the orally bioavailable FTI Tipifarnib administered for 21 days in patients with relapsed or refractory AML ([@b38-btt-2-491]). Consistent inhibition of FTase activity occurred at or above 300 mg bid orally and dose-limiting toxicity (DLT), manifested as readily reversible central neurotoxicity, was observed at 1200 mg bid. Oral absorption was rapid, with linear pharmacokinetics, and there was a dose-dependent increase in drug concentration in marrow with sustained levels 2- to 3-fold higher than concomitant levels in peripheral blood. Clinical responses were observed in 10 of 34 patients (29%), including 2 complete remissions (CRs) in patients with relapsed AML, and occurred across all dosing levels (100--900 mg bid) without strict relationship to the degree of leukemic cell FTase inhibition. Intriguingly, responses were independent of *ras* mutational status, as none of the 34 leukemic samples demonstrated an N-*ras* mutation ([@b38-btt-2-491]). Expansion of these findings in an international Phase II study ([@b34-btt-2-491]) yielded a CR rate of only 4% but, importantly, provided a template for subsequent studies of gene expression profiling to uncover determinants of response to tipifarnib ([@b60-btt-2-491]).

Based on the Phase I findings ([@b38-btt-2-491]), [@b46-btt-2-491] conducted a unique Phase II study of tipifarnib administered at a dose of 600 mg bid for 21 out of 28--63 days for 158 older adults with previously untreated, poor-risk AML. The median age was 74, 75% had antecedent MDS, and 47% had adverse cytogenetics. Treatment-related mortality was 7%. The CR rate in these elderly, poor-risk patients was 14% with an additional 10% partial response (partial remission, PR; hematologic improvement, HI). Among patients achieving CR, 82% had prior MDS and 40% had adverse cytogenetics. While median overall survival (OS) for all 158 patients was 5.3 months, median CR duration was 7.3 months and median OS for CR patients was 18.3 months. Patients who achieved PR or HI enjoyed a survival advantage as well, with a median OS 12.6 months. In contrast, median survival for patients who did not evince any type of response was 3.6 months. The lack of correlation between *ras* mutational status and clinical response was confirmed ([@b61-btt-2-491]). Measurements of inhibition of farnesylation of the chaperone protein HDJ-2 in marrow blasts obtained on day 8 of tipifarnib therapy revealed an increase in unfarnesylated protein in 75% of marrow samples, while inhibition of farnesylation of the nuclear membrane protein Lamin A could be detected in 92% of all concomitantly-obtained samplers of buccal mucosa ([@b46-btt-2-491]). This provocative finding may provide insight into potential mechanisms of FTI resistance, as discussed later in this review.

A randomized Phase III study of tipifarnib 600 mg bid for 21 out of 28 days vs best supportive care (including hydroxyurea) of 457 adults over age 70 with newly diagnosed, poor risk AML who were not fit for conventional chemotherapy was recently completed in Europe and Canada ([@b34-btt-2-491]). Durable CR (median DFS 8 months, median OS 22 months) was achieved in 8% of those randomized to tipifarnib, while there were no CRs in the supportive care/hydroxyurea arm. Disappointingly, however, there was no statistically significant OS benefit with tipifarnib treatment and the trial was deemed negative.

Explorations of alternative doses and schedules of tipifarnib are underway. The North American Intergroup conducted a Phase II 4-arm study of different doses (300 mg bid vs 600 mg bid) and schedules (daily × 21 days vs one week-on, one week-off) of single-agent tipifarnib as induction therapy for adults over age 70 with newly diagnosed AML ([@b21-btt-2-491]). While CRs and PRs were seen in all arms with acceptable toxicity profiles, the most salutary outcome was defined for those patients receiving tipifarnib 300 mg bid for 21 days, with a 20% overall response rate (15% CR, 5% PR) and a 1-year survival of roughly 30%. Molecular analyses aimed at predicting response are planned. In a similar vein, a Phase I dose-escalation trial of a 1-week-on, 1-week-off schedule in adults with relapsed and refractory AML has defined the maximal tolerated dose (MTD) as 1200 mg bid, with the DLT being renal toxicity, and achievement of CR in 3 of 9 treated at or near the MTD ([@b41-btt-2-491]).

Combinatorial approaches ([Table 2](#t2-btt-2-491){ref-type="table"})
---------------------------------------------------------------------

While FTIs demonstrate reproducible activities as single agents, the resultant outcomes are modest. In order to improve the robustness of these results, the full development of FTIs in the therapeutic armamentarium for hematologic (and other) malignancies will require the design and testing of rational combinations of FTIs with cytotoxic, biologic and immunomodulatory agents in both the laboratory and the clinic. This is a burgeoning area of investigation in both the clinical and the laboratory arenas.

The combination of tipifarnib with conventional ara-C and anthracycline-based chemotherapy is under study by multiple investigators in newly diagnosed AML patients. In a Phase I--II study in 95 patients ages 15--70 (median age 50) with newly diagnosed AML or high-risk MDS, the MD Anderson group ([@b18-btt-2-491]) added tipifarnib 300 mg bid to idarubicin plus ara-C (IA) induction and consolidation followed by 6 months of cyclical tipifarnib maintenance therapy. The addition of tipifarnib to IA induction yielded a 73% CR/CRp rate (64% CR, 9% CRp), which is identical to the group's data with IA alone in a historically similar population. With the addition of tipifarnib, CRs were achieved in 69% with adverse cytogenetics (13/19 of patients with −5/−7, 21/35 with other abnormalities) and 12/16 (75%) with FLT-3 mutations. Major grade 3 toxicities included reversible diarrhea, rash and hyperbilirubinemia, induction mortality was very low. Median CR duration with tipifarnib is 17 months (12 month CR duration with IA alone) and the median OS is roughly the same as with similar historical controls (70 weeks vs 65 weeks, respectively). Additional observation and direct comparison between IA and IA plus tipifarnib in a prospective randomized Phase III trial will be needed to determine if the outcome with tipifarnib is superior to IA alone.

In a similar vein, a group led by investigators at Princess Margaret Hospital in Toronto, Ontario, Canada have conducted a Phase I dose-escalation study of tipifarnib added to conventional ara-C plus daunorubicin on days 6--15 of induction and consolidation therapies for newly diagnosed adults age 60 and older ([@b9-btt-2-491]), with achievement of CR in 9/22 (41%) and 2 PR, for an overall response rate of 50%. Of 7 with adverse cytogenetics 3 (43%) achieved CR and 1 achieved PR. Tipifarnib dose escalation up to 600 mg bid was well tolerated, albeit with mildly increased gastrointestinal toxicity, and a Phase II study with tipfiarnib at 600 mg bid days 6--15 plus ara-C and daunorubicin is under development for adults ≥60 years.

While it is possible that the antileukemic effects of tipifarnib might be enhanced by adjustment of the dose or schedule, an alternative approach would be to combine this agent with existing antileukemic therapy. Toward this end, preclinical studies have revealed that the antiproliferative effects in human AML cells in vitro are additive when tipi-farnib is combined with cladrabine or fludarabine ([@b42-btt-2-491]) and synergistic when tipifarnib is combined with bortezomib ([@b74-btt-2-491]) or daunorubicin ([@b53-btt-2-491]). Interestingly, tipifarnib appears to inhibit the drug efflux activity of the prototypical drug resistance protein P-glycoprotein (P-gp) in a dose-dependent fashion in human acute T-lymphoblastic leukemia and AML cell lines in a manner that is independent of its FT inhibitory activity ([@b53-btt-2-491]). This P-gp inhibition may be a part of the synergistic interaction between tipifarnib and daunorubicin and, at least in theory, could apply to combinations of tipifarnib with other P-gp substrates such as etoposide ([@b50-btt-2-491]; [@b53-btt-2-491]). Moreover, the ability of tipi-farnib to modulate P-gp activity and the possibility that such modulation could contribute to synergy with antileukemic agents such as daunorubicin and etoposide may have special relevance to elderly patients with AML, where high levels of P-gp expression are common and correlate with clinical drug resistance ([@b47-btt-2-491]; [@b2-btt-2-491]).

The topoisomerase II poison etoposide, which stabilizes covalent adducts between the nuclear enzyme topoisomerase II and DNA ([@b48-btt-2-491]; [@b70-btt-2-491]), has been used alone and in combination for acute leukemias and has demonstrated efficacy, particularly when combined with other cytotoxic agents ([@b23-btt-2-491]; [@b7-btt-2-491]; [@b8-btt-2-491]). Etoposide exhibits limited activity as a single agent when given intravenously in doses of 200--400 mg/m^2^ daily × 5 and orally at daily doses of 200--500 mg × 5--7 days ([@b23-btt-2-491]). Oral etoposide at doses of 75--125 mg/m^2^ (100--200 mg) daily × 3--5 has been combined with oral idarubicin at doses of 20--30 mg/m^2^ daily × 3--5 as induction therapy for small numbers of selected AML patients \>55 years ([@b36-btt-2-491]; [@b56-btt-2-491]; [@b26-btt-2-491]), with CR rates ranging from 0% to 30% but with short CR durations ([@b36-btt-2-491]; [@b26-btt-2-491]) and significant treatment-related toxicity and death ([@b56-btt-2-491]; [@b26-btt-2-491]).

A multicenter Phase I trial of oral tipifarnib plus oral etoposide (T + E) was designed with escalating doses of both drugs and exploration of two different durations of tipifarnib administration (14 vs 21 days) to examine the safety and tolerability of T + E in patients ≥70 years who were not candidates for conventional induction chemotherapy and to preliminarily assess the antileukemic activity of the combination ([@b39-btt-2-491]). A total of 84 patients (median age 77) received 224 cycles of tipifarnib (300--600 mg bid for 14 or 21 days) + etoposide (100--200 mg daily on days 1--3 and 8--10). All patients had at least 1 poor-risk feature in addition to age, including secondary AML (55%), adverse cytogenetics (54%), and/or 3 or more non-hematologic co-morbidities (45%). In the previous phase II study of single-agent tipifarnib administered at 600 mg bid for 21 consecutive days, grade 3 or 4 adverse events occurred in 47% of in elderly AML patients ([@b46-btt-2-491]). When the same 21-day schedule of tipifarnib was combined with etoposide, grade 4 oral mucositis, grade 3 hyperbilirubinemia, and multi-organ failure were detected at tipifarnib doses of 400 mg twice daily, independent of etoposide dose. In contrast, the same etoposide schedule was much better tolerated when tipifarnib was administered for 14 days without any dose limiting toxicities, even at a tipifarnib dose of 600 mg bid. Oral mucositis, a well-known toxicity of etoposide, has not accompanied previous studies of single-agent tipifarnib ([@b38-btt-2-491]; [@b44-btt-2-491]; [@b25-btt-2-491]; [@b46-btt-2-491]) The apparent relationship between tipifarnib schedule and mucositis induction may represent synergy between tipifarnib and etoposide against normal oral mucosa. On the other hand, tipifarnib-related neurotoxicity was not enhanced by combination with etoposide.

For the entire group of 84 patients, the CR rate was 25%, with median CR duration being 9.8 months (range 3--31 months) and median OS being 22 months (range 3.5--36+), with 67% surviving for more than 1 year and 43% alive at 16+ to 36+ months. When the relationship between dose or schedule and response was examined, CR was achieved in 31% of the patients receiving tipifarnib doses of at least 400 mg twice daily and in 16/54 (30%) patients receiving 14-day T vs 5/30 (17%) receiving 21-day. Interestingly, CR rates of 50% (3/6 patients per cohort) were achieved in three of the 14-day cohorts where tipifarnib dose was at least 400 mg twice daily in combination with etoposide at 100 or 200 mg daily. Thus, this combination has yielded encouraging clinical results, with a CR rate that is almost double that achieved with tipifarnib alone ([@b46-btt-2-491]) in a group of patients for whom traditional antileukemia chemotherapy may not be appropriate because of advanced age, poor risk biologic disease features, and/or the presence of significant non-hematologic co-morbidities ([@b2-btt-2-491]; [@b22-btt-2-491]). In view of the results observed, a randomized multicenter Phase II trial is planned to compare two 14-day cohorts to select the optimal doses of T+E that will produce the maximal CR rate with the most acceptable toxicity profile.

Treatment of minimal residual disease: maintenance therapy
==========================================================

Maintenance chemotherapy in CR after multiple cytotoxic regimens is effective in the setting of acute lymphoblastic leukemia but has not yet proven to lengthen CR in AML, particularly in older patients or those with poor-risk features ([@b15-btt-2-491]; [@b49-btt-2-491]; [@b30-btt-2-491]; [@b12-btt-2-491]; [@b22-btt-2-491]). Nonetheless, the concept of maintenance therapy after intensive therapy is appealing if indeed such therapy could prolong CR or prevent relapse without incurring serious toxicities or clonal evolution of remaining leukemic cells. It is becoming increasingly possible to identify AML patients whose CR durations are predicted to be short, based on clinical and biologic features that reflect inherent drug resistance (Harris et al 1999; [@b32-btt-2-491]; [@b3-btt-2-491]; [@b13-btt-2-491]; [@b73-btt-2-491]; [@b58-btt-2-491]; [@b22-btt-2-491]; [@b52-btt-2-491]). Indeed, in adults with one or more poor-risk features, the median CR duration is ≤9 months and the 1-year DFS is 20% ([@b4-btt-2-491]; [@b30-btt-2-491]; [@b67-btt-2-491]; [@b8-btt-2-491]; [@b10-btt-2-491]; [@b22-btt-2-491]). In such patients, the so-called "minimal residual disease" (MRD) state should provide a fertile testing ground for new approaches aimed at prolonging CR and preventing or deterring relapse.

In this regard, it is reasonable to speculate that FTIs might suppress regrowth of the malignant clone when the residual tumor burden after cytotoxic chemotherapies has been reduced to a minimal state. This concept has now been tested in patients with AML with poor-risk features in first CR who are expected to relapse in less than 1 year (age ≥ 60 and/or secondary AML or adverse cytogenetics) (Karp et al 2008). In a Phase II trial of tipifarnib monotherapy for 48 such adults with poor-risk AML in first CR, tipifarnib 400 mg bid for 14 out of 21 days was initiated after recovery from consolidation chemotherapy, for a maximum 16 cycles. Twenty (42%) completed 16 cycles, 24 (50%) were removed from study for relapse, and 4 (8%) discontinued drug prematurely for intolerance. Non-hematologic toxicities were rare, but tipifarnib dose was reduced in 58% for myelosuppression. Median DFS was 13.5 months (range 3.5--60+), with 30% having DFS ≥ 2 years. When CR durations for patients who received tipifarnib maintenance were compared with the CR durations of historically similar patients who received the same induction and consolidation therapies but did not receive tipifarnib, DFS for patients with secondary AML (p = 0.01), adverse cytogenetics (p = 0.07), or both poor-risk features (p = 0.02) appeared to be prolonged with tipifarnib. This effect of tipifarnib for patients with secondary AML and/or adverse cytogenetics is consistent with previous demonstrations of tipifarnib activity in patients with high-risk MDS ([@b25-btt-2-491]) and in elderly patients with MDS/AML including those with adverse cytogenetics ([@b39-btt-2-491]; [@b46-btt-2-491]). On the other hand, historical comparison suggested that tipifarnib maintenance may not prolong DFS in patients whose sole risk factor was age ≥ 60 and whose AML did not exhibit poor risk biology. A randomized trial, as is currently underway in the Eastern Cooperative Oncology Group (ECOG), will be needed to demonstrate any definitive benefit of tipifarnib as post-remission maintenance therapy for any subgroups of patients with AML with poor-risk features, in particular those with secondary AML and/or adverse cytogenetics.

One future goal is to determine who will benefit from the addition of tipifarnib in the MRD setting. This may be particularly challenging in patients with normal cytogenetics, where clinical outcomes and cure rates can vary dramatically, reflecting heterogeneity on the molecular level ([@b13-btt-2-491]; [@b71-btt-2-491]; [@b52-btt-2-491]). In this regard, recent studies have defined single gene mutations and gene expression signatures that may help to discriminate prognostic subgroups in cytogenetically "normal" AML ([@b58-btt-2-491]; [@b52-btt-2-491]). In sum, the results of this limited Phase II study suggest that some patients with poor-risk AML, including those with secondary AML and/or adverse cytogenetics, may benefit from tipifarnib maintenance therapy without incurring clinically or biologically significant risks. Future studies of this approach should examine alternative tipifarnib dosing (eg, reduced dosing, different schedules) and continuation of therapy beyond 16 cycles, as well as a randomized, placebo-controlled trial of tipifarnib maintenance therapy. Finally, stratification based on molecular features may refine the ability to target the subset of patients who stand to derive the greatest benefit from the tipifarnib maintenance approach.

Resistance to tipifarnib
========================

Malignant cells have an uncanny ability to become resistant to new antitumor agents, and it is likely that the FTIs will be no exceptions. Such resistance, whether intrinsic or acquired, limits net drug efficacy. To date, resistance to FTIs has been demonstrated in diverse cell lines that have been developed via selective adaptation ([@b57-btt-2-491]; [@b66-btt-2-491]; [@b11-btt-2-491]; [@b14-btt-2-491]; [@b75-btt-2-491]) or have been genetically engineered to express FT enzyme mutations ([@b19-btt-2-491]; [@b62-btt-2-491]). For example, a tipifarnib-resistant human colon cancer cell line, generated by continuous drug exposure, exhibits a marked reduction in the FT enzyme itself without enzyme mutations or aberrations in activation of enzyme subunits ([@b57-btt-2-491]). In a similar construct, a lonafarnib-resistant Ph+ALL cell line from transgenic mice has been generated by growing those cells on stroma in the presence of increasing lonafarnib concentrations ([@b75-btt-2-491]). The resultant lonafarnib-resistant cells exhibit marked increase in gene expression of the novel ATP binding cassette (ABC) transporter homolog ATP11a and are, interestingly, relatively resistant to imatinib as well. A novel MM line derived from 8226 (8226/R5) exhibits resistance to both tipifarnib and bortezomib, with such resistance unrelated to FTase mutations, drug transporters, or heat shock protein expression ([@b14-btt-2-491]). In comparison with drug sensitive 8226 cells, gene expression profiling of the resistant 8226/R5 cells revealed increased expression of Jak2 and Stat1 with marked elevation in both phosphorylated Stat1 and Stat3 and, as a mRNA and result of activated Stat3, an increase in BCL-X~L~ protein expression. In addition, 8226/R5 cells were found to overexpress a particular isoform of the PI~3~K p110 subunit. It is reasonable to speculate that overexpression of key components of the PI~3~/AKT anti-apoptosis pathway by any mechanism might be expected to confer relative resistance to FTI-induced apoptosis. Indeed, this appears to be the case in the generation of resistance to lonafarnib in the HCT116 human colon cancer cell line, which appears to relate to an increase in Akt and/or its downstream intermediaries ([@b11-btt-2-491]). Whether or not any of these mechanisms of resistance are clinically relevant is not yet known. The elucidation of these and other mechanisms of resistance at both cellular and humoral levels of drug disposition is an important aspect of the ongoing clinical development of FTIs.

In the clinical arena, [@b29-btt-2-491] examined drug sensitivity profiles of pediatric leukemias, using a methyl-thiazole-tetrazolium (MTT) assay to compare tipifarnib responsiveness with traditional cytotoxic agents. T-cell ALLs and acute monoblastic AMLs exhibited the greatest tipifarnib sensitivity without correlation between *ras* mutational status or in vitro drug responsiveness but with correlation in AML samples between resistance to tipifarnib and resistance to anthracyclines or etoposide. These studies may be a useful template for understanding shared mechanisms of drug resistance among structurally diverse compounds and, in turn, providing insights into strategies by which to overcome such resistance factors.

Gene expression: insights into FTI mechanisms of action and prediction of response
==================================================================================

The ability to identify molecular predictors of response to specific drugs or drug combinations should direct the selection of a therapeutic approach that is most likely to induce meaningful clinical response. Toward this end, microarray technology provides a spectrum of gene expression signatures in AML which, in turn, affords a molecular stratification of patients with respect to disease biology and clinical outcome. [@b59-btt-2-491] have conducted serial studies of gene expression profiling in the context of AML cell lines and primary AML marrow cells exposed to tipifarnib in vitro, in marrow blasts from patients with relapsed and refractory AML undergoing treatment with tipifarnib alone ([@b34-btt-2-491]; [@b60-btt-2-491]), and most recently in marrow blasts from elderly adults with previously untreated AML with poor-risk features who received tipifarnib alone as induction therapy ([@b46-btt-2-491]; [@b61-btt-2-491]). Each of these studies has identified networks of differentially expressed genes and gene combinations capable of predicting response to single agent tipifarnib. The in vitro studies identified integrated gene networks whose activities are modulated in an orchestrated fashion to yield net cell death in diverse AML cell lines and in primary AML marrow samples, while the studies in AML cells from patients with relapsed and refractory AML identified a signature of 8 genes that are differentially expressed in responders vs nonresponders, with overexpression of one gene in particular, the lymphoid blast crisis oncogene (oncoLBC or AKAP13), capable of accurately predicting clinical response to tipifarnib ([@b60-btt-2-491]). Provocatively, the AKAP13 protein acts as a guanine nucleotide exchange factor for Rho proteins ([@b76-btt-2-491]; Toksoz et al 2004) and contains a region that is homologous to an α-helical domain known to interact with nuclear envelope protein lamin B ([@b27-btt-2-491]). This is especially intriguing because Rho and lamin proteins are farnesylated, and AKAP13 activates both types of proteins. The recent discovery that lamin B is critical to the assembly of the mitotic spindle ([@b69-btt-2-491]) makes it tempting to speculate that AKAP13 might have an indirect role in promoting or permitting completion of mitosis, perhaps in concert with another group of FTI targets, namely CENPs. Finally, gene expression profiles of AML marrow blasts from elderly adults with newly diagnosed, poor-risk AML ([@b61-btt-2-491]) demonstrate that response to tipifarnib relates to the expression of two specific genes: up-regulation of the gene encoding the guanine nucleotide exchange factor RASGRP1, which activates Ras, and down-regulation of *APTX,* the gene encoding the DNA excision repair protein aprataxin ([@b1-btt-2-491]). Conversely, active aprataxin may be able to repair damaged DNA in a way that uncouples the detection of that damage and the eventual completion of programmed cell death. It should be noted that the studies to date have been conducted in relatively small numbers of patients and may therefore be somewhat biased. Nonetheless, the continuing efforts to compare gene expression profiles of AML marrow blasts obtained pretreatment and during treatment with tipifarnib alone or in combination with other agents hold promise for identifying genomic markers that could accurately predict susceptibility vs resistance to tipifarnib-based therapies.

Perspectives for continuing clinical development of tipifarnib
==============================================================

In summary, tipifarnib inhibits malignant cell growth and survival by interfering with multiple intracellular signaling pathways. As a single agent, it has reproducible clinical effects on AML and other hematologic malignancies, but to date those effects are detected in a minority of patient subgroups. There are a number of potential explanations for the less-than-robust clinical results with FTIs as single agents, including inherent patient and disease heterogeneity, potential recruitment of survival pathways including DNA repair, and activation of other post-translational processing enzymes (eg, geranylgeranyltransferase) that might circumvent the effects of FT inhibition. As with all other malignancies, the optimal approach is likely to lie in rational combinations of tipifarnib or other FTIs with cytotoxic, biologic, and/or immunomodulatory agents with non-cross-resistant mechanisms of action. The clinical trials currently in progress will provide the critical foundations for defining the optimal roles of tipifarnib in patients with diverse hematologic malignancies.

The precise mechanisms by which tipifarnib exerts its cytotoxicity remain to be defined. The original notion that these agents targeted Ras mutations is clearly not complete, and it is likely that all FTIs have an impact on multiple molecules and pathways involved in cellular integrity. Studies to define the mechanisms by which tipifarnib alters cellular metabolism and modulate the activities of specific signaling pathways in normal and malignant precursors are a pivotal part of this effort. In this regard, the potential impact of FTIs on other disease processes is presaged by the ability of ABT-100 to ameliorate the process of premature aging in a mouse model of progeria which, like the human condition, is characterized by accumulation of an abnormally farnesylated form of the lamin A precursor prelamin A, disruption of orderly nuclear scaffolding, and resultant misshapen nuclei ([@b28-btt-2-491]). The clinical and correlative laboratory trials in progress and under development will provide the critical foundations for defining the optimal roles of tipifarnib and other FTIs in patients with cancer, and perhaps other diseases of disordered cellular metabolism as well.
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Trials of single agent tipifarnib in acute myelogenous leukemia

  Phase   Patient population                                 Tipifarnib[a](#tfn1-btt-2-491){ref-type="table-fn"} dose-schedule   Response rate                                              Author
  ------- -------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------- ------------------
  I       Rel/Ref[a](#tfn1-btt-2-491){ref-type="table-fn"}   100--1200, 21/28 days                                               CR 8% (2/34)                                               [@b38-btt-2-491]
                                                             MTD 900                                                             OR 29% (10/34)                                             
  I       Rel/Ref                                            400--1400, alternate week                                           CR 33% (3/9)                                               [@b41-btt-2-491]
                                                             MTD 1200                                                            @ MTD                                                      
  II      Rel/Ref                                            600, 21/28 days                                                     CR 7% (11/169)                                             [@b34-btt-2-491]
                                                                                                                                 sCR 4% (6/169)                                             
                                                                                                                                 med OS 12.2 mo                                             
  II      New Dx                                             600, 21/28--63 days                                                 CR 14% (22/158)                                            [@b46-btt-2-491]
          Poor risk                                                                                                              OR 23% (37/158)                                            
          Age ≥ 65                                                                                                               med DFS 7.3 mo                                             
                                                                                                                                 CR med OS 18.6 mo                                          
  II      New Dx                                             300--600, 21/28 days                                                CR 6--15%                                                  [@b21-btt-2-491]
          Age ≥ 70                                           vs alternate week                                                   CR 15%/OR 20%                                              
                                                                                                                                 @ 300 × 21/28 days                                         
  III     New Dx                                             600 mg, 21/28 days                                                  CR 8% (18/228)                                             [@b35-btt-2-491]
          Poor risk                                          vs BSC including HU                                                 med DFS 8 mo                                               
          Age ≥ 70                                           (vs 0% BSC/HU arm)                                                  CR med OS 20 mo[b](#tfn2-btt-2-491){ref-type="table-fn"}   

^a^mg bid.

^b^no significant difference between tipifarnib and BSC arms with regard to OS.

**Abbreviations:** Rel/Ref, relapsed/refractory; CR, complete remission; sCR, sustained complete remission; OR, overall response; MTD, maximal tolerated dose; DFS, disease-free survival; OS, overall survival; BSC, best supportive care; HU, hydroxyurea; mo, months.

###### 

Trials of tipifarnib in combination with chemotherapeutic agents

  Phase   Patient population   Dose-schedules   Response rate                     
  ------- -------------------- ---------------- --------------------------------- -----------------
  I       New Dx               300, 400, 600    etoposide                         CR 25% (21/84)
          Poor risk            14 vs 21 days    100, 150, 200 mg                  med DFS 9.8 mo
          Age ≥ 70                              Days 1--3 and 8--10               CR med OS 22 mo
          ([@b39-btt-2-491])                                                      
  I       New Dx               200--600         ara-C 100 mg/m^2^day CI × 7       CR 41% (9/22)
          Age ≥ 60             Days 6--15       daunorubicin 60 mg/m^2^/day × 3   OR 50% (11/22)
          ([@b9-btt-2-491])                                                       
  II      New Dx               300              ara-C 1.5 g/m^2^/day CI × 3--4    CR 69% (70/95)
          Age 17--61                            idarubicin 12 mg/m^2^/day         med DFS 17 mo
          ([@b18-btt-2-491])                                                      

^a^mg bid.

**Abbreviations:** CR, complete remission; CRp, complete remission with incomplete platelet recovery; DFS, disease-free survival; OR, overall response; OS, overall survival; mo, months.
